The Impact of 68Ga-DOTATOC PET/CT on the Multimodal Management of Patients with Neuroendocrine Tumors

#315

Introduction: Accurate assessment of the primary tumor site and the extent of the metastatic burden are crucial and can be challenging, however, it is essential to the choice of optimal patient-tailored management.

Aim(s): To evaluate the impact of 68Ga-DOTATOC (or 68Ga-DOTATE)* PET/CT on the multimodal management of neuroendocrine tumors (NET).

Materials and methods: A total of 58 patients (27 women, 31 men) with histologically proven NET could be included in the study of comparison between 68Ga-DOTATOC* PET/CT and CT and/or MRI. The examinations were performed in terms of tumor staging and, in some instances also of primary tumor site identification, to evaluate the patient’s eligibility for treatment.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Sotiropoulos G, Li J, Al-Nahhas A, Spalding D, Tedeschi M,

Keywords: neuroendocrine tumors, 68Ga-DOTATOC (or 68Ga-DOTATE) PET/CT, impact of surgical management,